Hussain Qusay Mohammed, Al-Hussainy Ali Fawzi, Sanghvi Gaurav, Roopashree R, Kashyap Aditya, Anand D Alex, Panigrahi Rajashree, Shavazi Nargiz, Taher Sada Ghalib, Alwan Mariem, Jawad Mahmood, Mushtaq Hiba
College of Pharmacy, Alnoor University, Mosul, Iraq.
College of Pharmacy, Ahl Al Bayt University, Kerbala, Iraq.
Eur J Med Res. 2025 May 19;30(1):393. doi: 10.1186/s40001-025-02618-z.
Tumor angiogenesis facilitates cancer progression by supporting tumor growth and metastasis. MicroRNA-155 (miR-155) plays a pivotal role in regulating angiogenesis through both direct effects on tumor and endothelial cells and indirect modulation via exosomal communication. This review highlights miR-155's pro-angiogenic influence on endothelial cell behavior and tumor microenvironment remodeling. Additionally, exosomal miR-155 enhances intercellular communication, promoting vascularization in several cancers. Emerging therapeutic strategies include miR-155 inhibition using antagomirs, exosome-mediated delivery systems, and modulation of pathways such as JAK2/STAT3 and TGF-β/SMAD2. Targeting miR-155 represents a promising approach to hinder tumor angiogenesis and improve cancer therapy outcomes.
肿瘤血管生成通过支持肿瘤生长和转移促进癌症进展。微小RNA-155(miR-155)在调节血管生成中起关键作用,其作用方式包括对肿瘤细胞和内皮细胞的直接影响以及通过外泌体通讯的间接调节。这篇综述重点介绍了miR-155对内皮细胞行为和肿瘤微环境重塑的促血管生成影响。此外,外泌体miR-155增强细胞间通讯,促进多种癌症中的血管生成。新兴的治疗策略包括使用抗miR-155寡核苷酸抑制miR-155、外泌体介导的递送系统以及调节JAK2/STAT3和TGF-β/SMAD2等信号通路。靶向miR-155是一种有前景的方法,可阻碍肿瘤血管生成并改善癌症治疗效果。
Discov Oncol. 2025-7-28
J Transl Med. 2025-7-8
Kidney Blood Press Res. 2022